Table 1.

Baseline characteristics of patients with RA treated with TCZ according to different BMI groups. Values are % or median (IQR) unless otherwise specified.

CharacteristicsWhole PopulationBMI, n = 207*p
< 25 kg/m225–30 kg/m2> 30 kg/m2
Patients, n (%)222121 (58.5)54 (26.0)32 (15.5)
Age, yrs56 (47–66)55 (46–65)58.5 (52–67)56 (48–63.5)0.29
Female sex82.483.577.893.70.15
Disease duration, yrs14 (8–22)15 (8–23.5)13 (8–24)11 (8.5–19)0.44
Erosive status79.083.575.062.50.03
RF-positive71.066.177.477.40.22
ACPA-positive65.767.263.564.50.88
Previous biologics use, median (min–max)2 (0–6)3 (0–6)2 (0–6)2 (0–6)0.08
Biologic-naive patients13.111.618.59.40.38
Concomitant therapy
  MTX, n (%)105 (47.3)58 (47.9)25 (46.3)14 (43.7)0.91
  MTX dose, mg/wk15 (10–15)15 (10–15)15 (10–15)15 (12.5–17.5)0.81
  Steroid, n (%)143 (64.7)79 (65.8)35 (64.8)21 (65.6)0.99
  Steroid dose, mg/day10 (5–10)10 (5–15)10 (5–10)8 (5–10)0.65
  TCZ dose, mg/kg, median (min–max)8 (4–8)8 (4–8)8 (8–8)8 (8–8)0.24
Disease activity measures
  TJC8 (5–13.5)7 (4–13)10 (5–16)8 (5.5–13)0.31
  SJC4 (1–7)4 (1–7)4 (2–7)3 (1–5)0.25
  ESR, mm/h27 (11–44)24 (10–39)28 (11–44)32 (21–57)0.07
  CRP, mg/l8.0 (3–24.5)6.3 (2.6–24.8)8.0 (2.5–22.1)11.2 (7.4–24.1)0.11
  DAS28-ESR, mean (SD)5.09 (1.28)5.04 (1.34)5.14 (1.36)5.22 (1.11)0.75
  • * 15 patients had missing values for weight and/or height. RA: rheumatoid arthritis; TCZ: tocilizumab; BMI: body mass index; IQR: interquartile range; RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; MTX: methotrexate; TJC: tender joint count; SJC: swollen joint count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints.